Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MDX2202
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : BARDA
Deal Size : $110.0 million
Deal Type : Funding
ModeX Secures $35M For COVID Antibodies, $16M For Influenza Program
Details : The funding will support the development of a novel multispecific antibody to SARS-CoV-2 from preclinical and influenza multispecifics with gene and/or protein delivery modalities.
Product Name : MDX2202
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
July 10, 2024
Lead Product(s) : MDX2202
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : BARDA
Deal Size : $110.0 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : BARDA
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement aims to advance a platform and specific candidates addressing a range of viral infectious diseases and will enable research, development and clinical evaluation of potent multispecific antibodies, based on ModeX proprietary MSTAR technology...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 28, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : BARDA
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : OPKO Health
Deal Size : $300.0 million
Deal Type : Acquisition
Details : ModeX Therapeutics has developed highly flexible multi-specific antibody technology platforms with broad targeting and functional capabilities, simpler manufacturing and potentially better specificity and safety, providing significant differentiation fro...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
September 05, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : OPKO Health
Deal Size : $300.0 million
Deal Type : Acquisition